Deckers Down, Nokia Up: Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 23, 2026

Upside

– $CCI +11%, SBAC +9.9%, AMT +8.5% (tower operators rise after a report that SpaceX is discussing infrastructure partnerships for a nationwide wireless buildout)

– $NOK +5.2% (Q3 profit beat as AI-and-cloud sales more than doubled and order intake surged)

– $LITE +3.5%, AAOI +2.3%, COHR +2.3% (optical-networking names gain on read-through from Nokia’s sharp AI-and-cloud order growth)

– $BAH +1.9% (Q2 profit beat offset a slight revenue miss)

– $TECK +1.7% (copper-linked stocks rise as copper prices advance)

Downside

– $FLG -8.3% (Q3 profit and revenue missed expectations)

– $DECK -8.2% (quarterly sales missed and the FY sales outlook was cut, while the higher EPS guide relied partly on tariff refunds)

– $INFY -8.2% (FY revenue-growth guidance was cut to 1%-2% despite strong large-deal wins)

– $ALV -5.2% (Q3 profit and sales missed as cost headwinds weighed on results)

– $CRDO -4.6% (AI-infrastructure hardware weakness continues amid concerns over the pace and returns of sector spending)

– $TMUS -4.5%, T -4.4%, VZ -3.9% (wireless carriers fall after a report that SpaceX is pursuing a nationwide cellular-infrastructure program)

– $BE -3.9% (record results and raised guidance were not enough after a major AI-power rally)

– $MRNA -3.7% (extends losses following leaked cancer-vaccine data that disappointed investors)

– $FIX -3.1% (earnings beat, but the CFO retirement and elevated expectations drive a sell-the-news reaction)

– $ACN -2.7%, $CTSH -2.0% (IT-services names fall after Infosys cut its FY growth outlook)

– $WDC -1.9%, STX -1.4% (storage names retreat despite WDC’s beat-and-raise report as elevated expectations trigger profit-taking)

Netflix Down, SpaceX Up: Upside/Downside Movers in the A.M.

Avatar photo Doug Kass on October 21, 2026

Upside

– $SMCI +12% (preliminary fiscal Q1 revenue outlook was raised well above expectations, with gross-margin upside)

– $SPCX +8.2% (Q3 revenue and profit crushed expectations, marking its first quarterly profit since the IPO, while special committees evaluate a potential TSLA merger)

– $CRDO +7.2%, $VRT +6.7%, $DELL +6.9%, $LITE +5.6%, $HPE +5.0%, $COHR +4.6% (AI-infrastructure suppliers rise as the SMCI outlook and SPCX AI-compute results reinforce data-center demand)

– $WDC +4.0%, $SKHY +3.7%, $SNDK +3.7%, $STX +3.6%, $MU +3.1% (memory and storage names gain on the stronger AI-infrastructure demand read-through)

– $APLD +4.0% (Texas AI data-center agreement and bullish analyst action)

– $INTC +2.3%, AMD +2.1%, $NVDA +2.0% (chip stocks rise as strong AI-compute and server demand updates lift the broader complex)

– $TSLA +1.4% (special committee formed with SPCX to evaluate a potential merger ahead of earnings)

Downside

– $TKNO -30% ($40M primary offering priced at $5 per share, a steep discount to the prior close)

– $NFLX -7.0% (Q3 profit beat, but the Q4 sales outlook missed and the 2026 advertising-revenue forecast was cut to $2.7B from $3B)

– $ISRG -6.7% (Q3 beat, but U.S. procedure growth slowed, instrument pricing reductions were outlined and the high end of the procedure-growth outlook was cut)

– $T -5.6% (Q3 beat and FY EPS guidance was raised, but postpaid phone additions missed expectations amid satellite-competition concerns)

– $DHR -3.6% (Q3 beat and FY EPS guidance was raised, but the Q4 core-growth outlook remained modest with a respiratory-revenue headwind)

– $TMO -3.0% (sell-the-news reaction after a Q3 beat and raised FY guidance)

– $ACN -1.5% (Baird downgrades to Neutral from Outperform on valuation and slower organic growth)

Select Premarket Movers

Avatar photo Doug Kass on October 14, 2026

Upside

– $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization)

– $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029)

– $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 plan)

– $ENVX +10.0% (received a 100,000-battery drone order and reported preliminary Q3 revenue above guidance)

– $BLK +5.0% (Q3 beat as $205B of net inflows and strong organic base-fee growth topped expectations)

– $ACN +4.0% (investor day targets)

Downside

– $BMEA -20.0% (Phase 1 BMF-650 weight-loss data disappointed investors despite no severe or serious treatment-emergent events)

– $STT -8.5% (Q3 EPS was roughly in line, but revenue missed and fee revenue declined sequentially)

– $FAST -4.5% (Q3 revenue came in slightly light and the 2026 device-signings target was trimmed despite an EPS beat and better operating margin)

– $BAC -4.5% (Q3 adjusted EPS and revenue missed as a $1.2B regulatory-settlement charge weighed on results)

– $HPE -4.5%, NTAP -4.0%, DELL -3.0% (Barclays downgrades the hardware names to Equal Weight, citing valuation and a lack of meaningful AI-driven growth inflection)

– $CRWV -4.0% (no clear fresh company-specific catalyst identified; unusually large premarket move)

Position: None

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 1, 2026

Upside

– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)

– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)

– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)

– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)

– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)

– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)

– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)

– $IBM +5.7% (unveils a self-hosted enterprise AI model)

– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)

– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)

– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)

– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)

– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)

– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)

– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)

Downside

– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)

– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)

– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)

– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)

– $BGIN -10% (slides following first-half results)

– $IVA -10% (extends weakness following unaudited first-half results and corporate update)

– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)

– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)